PMID- 32579486
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2687-8941 (Electronic)
IS  - 2687-8941 (Linking)
VI  - 6
DP  - 2020 Jun
TI  - Chronic Lymphocytic Leukemia: Real-World Data From India.
PG  - 866-872
LID - 10.1200/GO.20.00032 [doi]
LID - GO.20.00032
AB  - PURPOSE: Chronic lymphocytic leukemia (CLL) is uncommon in India. There are 
      limited studies on CLL from the Indian subcontinent. METHODS: This was a 
      prospective study (2011-2017) of consecutively diagnosed patients with CLL at a 
      single center. The diagnosis, prognosis, treatment indication, response criteria, 
      and adverse events were recorded as per International Workshop on Chronic 
      Lymphocytic Leukemia guidelines. Biosimilar rituximab dosing (375 mg/m(2)) was 
      fixed for all cycles. Time to next treatment (TTNT) was defined as the time from 
      front-line treatment initiation to next treatment or death from any cause. 
      Overall survival (OS) was defined as the time from treatment initiation until 
      death from any cause. RESULTS: A total of 409 patients with CLL were enrolled 
      over the study period. The median follow-up was 32 months (range, 2-135 months). 
      The median age was 61 years, and 31.8% of patients with CLL were </= 55 years of 
      age; 43.3% of patients had a cumulative illness rating scale score >/= 3. 
      Prognostic fluorescence in situ hybridization data were available in 53.3% of 
      patients. Chlorambucil (94/180; 52.2%) and bendamustine + rituximab (BR; 57/180; 
      31.6%) were the most common regimens used up front. The overall response rates 
      after front-line therapy were 74.4% and 91.2%, respectively. The TTNT was 33 
      months and not reached, respectively (P = .001). Grade 3/4 neutropenia and 
      infections were seen in 52.6% and 38.5% of patients receiving BR. The median OS 
      was not reached in both regimens (P = .25). CONCLUSION: Indian patients with CLL 
      are younger in chronological age but have higher morbidity burden. Treatment 
      outcomes with biosimilar fixed-dose BR are comparable to those reported in the 
      literature. Chlorambucil is still a valid option, given the economic burden of 
      the disease and treatment.
FAU - Tejaswi, V
AU  - Tejaswi V
AD  - Department of Internal Medicine, Postgraduate Institute of Medical Education and 
      Research, Chandigarh, India.
FAU - Lad, Deepesh P
AU  - Lad DP
AD  - Department of Internal Medicine, Postgraduate Institute of Medical Education and 
      Research, Chandigarh, India.
FAU - Jindal, Nishant
AU  - Jindal N
AD  - Department of Internal Medicine, Postgraduate Institute of Medical Education and 
      Research, Chandigarh, India.
FAU - Prakash, Gaurav
AU  - Prakash G
AD  - Department of Internal Medicine, Postgraduate Institute of Medical Education and 
      Research, Chandigarh, India.
FAU - Malhotra, Pankaj
AU  - Malhotra P
AD  - Department of Internal Medicine, Postgraduate Institute of Medical Education and 
      Research, Chandigarh, India.
FAU - Khadwal, Alka
AU  - Khadwal A
AD  - Department of Internal Medicine, Postgraduate Institute of Medical Education and 
      Research, Chandigarh, India.
FAU - Jain, Arihant
AU  - Jain A
AD  - Department of Internal Medicine, Postgraduate Institute of Medical Education and 
      Research, Chandigarh, India.
FAU - Sreedharanunni, Sreejesh
AU  - Sreedharanunni S
AD  - Department of Hematology, Postgraduate Institute of Medical Education and 
      Research, Chandigarh, India.
FAU - Sachdeva, Manupdesh Singh
AU  - Sachdeva MS
AD  - Department of Hematology, Postgraduate Institute of Medical Education and 
      Research, Chandigarh, India.
FAU - Naseem, Shano
AU  - Naseem S
AD  - Department of Hematology, Postgraduate Institute of Medical Education and 
      Research, Chandigarh, India.
FAU - Varma, Neelam
AU  - Varma N
AD  - Department of Hematology, Postgraduate Institute of Medical Education and 
      Research, Chandigarh, India.
FAU - Varma, Subhash
AU  - Varma S
AD  - Department of Internal Medicine, Postgraduate Institute of Medical Education and 
      Research, Chandigarh, India.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - JCO Glob Oncol
JT  - JCO global oncology
JID - 101760170
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - India/epidemiology
MH  - *Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy/epidemiology
MH  - Middle Aged
MH  - Prospective Studies
PMC - PMC7328099
COIS- The following represents disclosure information provided by authors of this 
      manuscript. All relationships are considered compensated unless otherwise noted. 
      Relationships are self-held unless noted. I = Immediate Family Member, Inst = My 
      Institution. Relationships may not relate to the subject matter of this 
      manuscript. For more information about ASCO's conflict of interest policy, please 
      refer to www.asco.org/rwc or ascopubs.org/go/site/misc/authors.html. Open 
      Payments is a public database containing information reported by companies about 
      payments made to US-licensed physicians (Open Payments). No potential conflicts 
      of interest were reported.
EDAT- 2020/06/25 06:00
MHDA- 2021/07/29 06:00
PMCR- 2020/06/24
CRDT- 2020/06/25 06:00
PHST- 2020/06/25 06:00 [entrez]
PHST- 2020/06/25 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2020/06/24 00:00 [pmc-release]
AID - 2000032 [pii]
AID - 10.1200/GO.20.00032 [doi]
PST - ppublish
SO  - JCO Glob Oncol. 2020 Jun;6:866-872. doi: 10.1200/GO.20.00032.